;Since the majority of this reshaped human antibody is derived from a human antibody and mouse CDRs have a low level of antigenicity, the reshaped human antibody of the present invention has a low level of antigenicity in humans, and is therefore expected to be useful as a therapeutic agent and diagnostic tool for brain tumors such as medulloblastoma which strongly express antigen that is recognized by this antibody."/>
公开/公告号US7563599B2
专利类型
公开/公告日2009-07-21
原文格式PDF
申请/专利号US20040839799
申请日2004-05-06
分类号C12P21/04;C07H21/04;C12P21/08;C07K16/00;
国家 US
入库时间 2022-08-21 19:31:21